Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology)

Basit Öğe Kaydı
dc.contributor.authorInal, Ali
dc.contributor.authorKos, F. Tuba
dc.contributor.authorAlgin, Efnan
dc.contributor.authorYildiz, Ramazan
dc.contributor.authorBerk, Veli
dc.contributor.authorUnek, Ilkay T.
dc.contributor.authorColak, Dilsen
dc.date.accessioned2024-04-24T17:24:56Z
dc.date.available2024-04-24T17:24:56Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim of the study: Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected carefully. The aim of the study was to search for prognostic factors for survival in patients with gemcitabine (Gem)-refractory or with gemcitabine and cisplatin (GemCis)-refractory advanced pancreatic cancer. Material and methods: We retrospectively evaluated patients with Gem-or GemCis-refractory advanced pancreatic cancer. Sixteen potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival. Univariate and multivariate statistical methods were used to determine prognostic factors. Results: Multivariate analysis included the four prognostic significance factors in univariate analysis. Multivariate analysis showed that liver metastasis and second-line chemotherapy were considered independent prognostic factors for survival. Conclusions: Liver metastasis and second-line chemotherapy were identified as important prognostic factors in advanced pancreatic cancer patients refractory to treatment with Gem or GemCis. This prognostic factors may also facilitate pretreatment prediction of survival and can be used for selecting patients for treatment.en_US
dc.identifier.doi10.5114/wo.2014.43933
dc.identifier.endpage129en_US
dc.identifier.issn1428-2526
dc.identifier.issn1897-4309
dc.identifier.issue2en_US
dc.identifier.pmid26034390
dc.identifier.scopus2-s2.0-84929412681
dc.identifier.scopusqualityQ2
dc.identifier.startpage125en_US
dc.identifier.urihttps://doi.org/10.5114/wo.2014.43933
dc.identifier.urihttps://hdl.handle.net/11468/19885
dc.identifier.volume19en_US
dc.identifier.wosWOS:000422085900007
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTermedia Publishing House Ltden_US
dc.relation.ispartofWspolczesna Onkologia-Contemporary Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPancreatic Canceren_US
dc.subjectGemcitabine-Refractoryen_US
dc.subjectPatientsen_US
dc.subjectPrognostic Factorsen_US
dc.titlePrognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology)en_US
dc.titlePrognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology)
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu